Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of drugs initially developed to treat type 2 diabetes and are now becoming more widely used for obesity. They work by mimicking the actions of the GLP-1 hormone, which is released by the gut after eating. GPs will be used to prescribing them for type 2 diabetes, but less so for obesity. 

In this podcast, Dr Thomas Round discusses the evolving role of GLP1-RA in obesity, the benefits and potential side effects, the role of the GP, and the latest NICE guidance in this area with Dr Stephanie DiGiorgio, an urgent care GP with a specialist interest in obesity.